BeOne Medicines Demonstrates Scientific Leadership in B-Cell Cancers at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a rapidly expanding global oncology innovator, is set to showcase one of the most comprehensive and data-rich hematology portfolios at…
Oncolytics Biotech® Aligns with FDA on Pivotal Phase 3 Study Design for Pelareorep in First-Line Metastatic Pancreatic Cancer Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company advancing pelareorep, announced that it has reached alignment with…
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Strategy for BOT/BAL and Early-Access Programs Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its long-standing leadership in immuno-oncology, announced the appointment of José Iglesias, M.D.,…
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a novel gene editing platform designed to counteract drug resistance in…
Solve Therapeutics Raises $120 Million to Accelerate Next-Generation ADC Development for Solid Tumors Solve Therapeutics, a rapidly advancing clinical-stage biotechnology company focused on creating best-in-class antibody–drug conjugates (ADCs) for the treatment of solid tumor malignancies, announced that it has secured…
JSR Life Sciences Announces Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings, Marking a Significant Strategic Realignment in Oncology Research Services JSR Life Sciences LLC (“JSR Life Sciences”), a global leader in life sciences materials, bioprocessing solutions, and research…
Flightpath Biosciences Advances Precision Anti-Infective Strategy with New Drug License and Corporate Rebrand as Company Enters Next Phase of Growth Flightpath Biosciences, a clinical-stage biotechnology company committed to developing innovative treatments for infection-associated complex diseases, has announced a significant milestone…
KORU Medical Systems Reports 27% Third Quarter Revenue Growth and Raises Full-Year 2025 Guidance KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology firm dedicated to the development, manufacturing, and commercialization of patient-centric large-volume…
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business and Scientific Updates AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing novel small-molecule therapeutics using its proprietary boron chemistry platform, today announced its financial…
Dyno Therapeutics and Trisk Bio Forge Strategic Manufacturing Alliance to Advance Genetic Agency through Expanded Frontiers Program Dyno Therapeutics, Inc., a genetic technologies company leveraging artificial intelligence (AI) to revolutionize in vivo gene delivery, has announced a landmark manufacturing partnership…
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® Plus LENVIMA® in Advanced Endometrial Carcinoma The U.S. Food and Drug Administration (FDA) has officially approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic…
PharmaEssentia USA Appoints Dr. Barry Flannelly as Independent Director, Strengthening Leadership Amid Expanding Global Ambitions PharmaEssentia USA Corporation, a wholly owned subsidiary of PharmaEssentia Corporation (TWSE: 6446), today announced the appointment of Barry Flannelly, Pharm.D., MBA, as an Independent Director…